EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long-Term Pioglitazone Treatment Has No Significant Impact on Microglial Activation and Tau Pathology in P301S Mice

Lea Helena Kunze iD, François Ruch, Gloria Biechele iD, Florian Eckenweber, Karin Wind-Mark, Lina Dinkel, Paul Feyen, Peter Bartenstein, Sibylle Ziegler, Lars Paeger iD, Sabina Tahirovic iD, Jochen Herms und 1 weitere

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241210106 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Lea Helena Kunze und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital of LMU Munich, Marchioninistraße 15, 81377 Munich, Germany. Hauptthemen laut MEDLINE: Tauopathies, Alzheimer Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Munich Cluster for Systems Neurology, Alzheimer's Association Grant, AD Strategic Fund, Deutsche Forschungsgemeinschaft (DFG).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuroinflammation is one disease hallmark on the road to neurodegeneration in primary tauopathies. Thus, immunomodulation might be a suitable treatment strategy to delay or even prevent the occurrence of symptoms and thus relieve the burden for patients and caregivers. In recent years, the peroxisome proliferator-activated receptor γ (PPARγ) has received increasing attention as it is immediately involved in the regulation of the immune system and can be targeted by the anti-diabetic drug pioglitazone. Previous studies have shown significant immunomodulation in amyloid-β (Aβ) mouse models by pioglitazone. In this study, we performed long-term treatment over six months in P301S mice as a tauopathy model with either pioglitazone or placebo. We performed serial 18 kDa translocator protein positron-emission-tomography (TSPO-PET) imaging and terminal immunohistochemistry to assess microglial activation during treatment. Tau pathology was quantified via immunohistochemistry at the end of the study. Long-term pioglitazone treatment had no significant effect on TSPO-PET, immunohistochemistry read-outs of microglial activation, or tau pathology levels in P301S mice. Thus, we conclude that pioglitazone modifies the time course of Aβ-dependent microglial activation, but does not significantly modulate microglial activation in response to tau pathology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TauopathiesAlzheimer DiseaseMiceAnimalsPioglitazoneMicrogliaAmyloid beta-PeptidesPPAR gammaMice, Transgenictau ProteinsDisease Models, Animal

Stichwörter der Autor:innen

TSPO-PETmicrogliapioglitazone

Substanzen

PioglitazoneAmyloid beta-PeptidesPPAR gammatau Proteins

Autor:innen und Institutionen

  • Department of Nuclear Medicine, University Hospital of LMU Munich, Marchioninistraße 15, 81377 Munich, Germany.
  • German Center for Neurodegenerative Diseases (DZNE) Munich, Feodor-Lynen-Str. 17, 81377 Munich, Germany.
  • Department of Radiology, University Hospital of LMU Munich, Marchioninistraße 15, 81377 Munich, Germany.
  • Munich Cluster for Systems Neurology (SyNergy), Ludwig Maximilian University of Munich, 81377 Munich, Germany.
  • Center for Neuropathology and Prion Research, LMU Munich, Feodor-Lynen-Str. 23, 81377 Munich, Germany.

ORCID-Profile: Lea Helena Kunze, Gloria Biechele, Lars Paeger, Sabina Tahirovic

Förderung

  • Munich Cluster for Systems Neurology
  • Alzheimer's Association Grant, AD Strategic Fund
  • Deutsche Forschungsgemeinschaft (DFG)
  • Alzheimer’s Association Grant, AD Strategic Fund

Zitieren

APA

Kunze, L. H., Ruch, F., Biechele, G., Eckenweber, F., Wind-Mark, K., Dinkel, L., Feyen, P., Bartenstein, P., Ziegler, S., Paeger, L., Tahirovic, S., Herms, J., & Brendel, M. (2023). Long-Term Pioglitazone Treatment Has No Significant Impact on Microglial Activation and Tau Pathology in P301S Mice. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241210106

Vancouver

Kunze LH, Ruch F, Biechele G, Eckenweber F, Wind-Mark K, Dinkel L, et al. Long-Term Pioglitazone Treatment Has No Significant Impact on Microglial Activation and Tau Pathology in P301S Mice. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241210106

BibTeX
@article{Kunze2023,
  author = {Kunze, Lea Helena and Ruch, François and Biechele, Gloria and Eckenweber, Florian and Wind-Mark, Karin and Dinkel, Lina and Feyen, Paul and Bartenstein, Peter and Ziegler, Sibylle and Paeger, Lars and Tahirovic, Sabina and Herms, Jochen and Brendel, Matthias},
  title = {Long-Term Pioglitazone Treatment Has No Significant Impact on Microglial Activation and Tau Pathology in P301S Mice},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241210106}
}
Kostenlos starten →